Todas as matérias desta categoria, das mais recentes às mais antigas.
AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers. Sam Fazeli of Bloomberg Intelligence says a takeover would make no sense.
Two Republican senators are backing a deal with acting Attorney General Todd Blanche to formally rescind an order creating an "anti-weaponization fund," likely paving the way for Blanche's confirmation as the nation's top law enforcement officer. Jeff Mason reports on Bloomberg Television.
US and Japanese officials warned investors they're determined to keep defending the yen after their first joint intervention in 15 years. The yen surged Monday morning. Bloomberg's Cameron Crise talks about what the US and Japan hope to achieve.
Alexander’s (NYSE:ALX) reported Q2 net income of $155.4 million, or $30.24 per diluted share, following a major property-sale gain.
Giftify (NASDAQ:GIFT) reported Q2 gross billings of $45.5 million, up 26.2%, while net sales increased 4.0% to $21.7 million.
Douglas Dynamics (NYSE:PLOW) announced its financial results for the second quarter of 2026, reporting record net sales of $214.6 million.
TG Therapeutics (NASDAQ:TGTX) reported Q2 global revenue of $240.3 million as U.S. BRIUMVI sales increased 64% to $227.7 million.
AstraZeneca (NASDAQ:AZN) has reportedly engaged in early-stage negotiations regarding a potential merger with Bristol Myers Squibb (NYSE:BMY).
Sportradar (NASDAQ:SRAD) reported Q2 revenue of €378 million, up 19%, while adjusted EBITDA increased 19% to €76 million.
Ocular Therapeutix (NASDAQ:OCUL) reported Q2 revenue of $13.5 million and plans a Q4 AXPAXLI filing after FDA alignment.
IBM Vice Chairman Gary Cohn says, "the market became addicted to knowing what the Fed was going to do" as he discusses market reaction to Federal Reserve Chairman Kevin Warsh's handling of the US central bank. Cohn also discusses Japan and the US Treasury Department working together to shore up the yen and the instabilities being dealt with by markets. He speaks on "Bloomberg Surveillance."
Krystal Biotech (NASDAQ:KRYS) reported Q2 VYJUVEK revenue of $119.2 million, up 24%, and net income of $54.8 million.
